<DOC>
	<DOCNO>NCT02927665</DOCNO>
	<brief_summary>The ReShape Post Approval Study prospective multicenter study ReShape ( TM ) Integrated Dual Balloon System Obese Subjects .</brief_summary>
	<brief_title>A Prospective Multicenter Post Approval Study ReShape™ Integrated Dual Balloon System Obese Subjects</brief_title>
	<detailed_description>The ReShape Post Approval Study post-approval , multicenter , single arm , open label clinical study intend collect valid scientific evidence regard safety efficacy ReShape Dual Balloon adjunct diet exercise treatment BMI 30-40 subject one obesity-related comorbid condition commercial clinical setting .</detailed_description>
	<criteria>1 . Ages 22 old 2 . Baseline BMI 30 40 3 . Failed weight reduction diet exercise alone 4 . One obesityrelated comorbid condition 5 . If female child bear potential , willing avoid pregnancy course treatment 1 . Prior gastrointestinal surgery sequela , i.e . obstruction , and/or adhesive peritonitis know abdominal adhesion 2 . Prior open laparoscopic bariatric surgery . 3 . Any inflammatory disease gastrointestinal tract include esophagitis , gastric ulceration , duodenal ulceration , cancer specific inflammation Crohn 's disease . 4 . Potential upper gastrointestinal bleeding condition esophageal gastric varix , congenital acquire intestinal telangiectasis , congenital anomaly gastrointestinal tract atresias stenosis . 5 . A gastric mass . 6 . A hiatal hernia &gt; 5 cm ≤ 5 cm associate severe intractable gastroesophageal reflux symptom . 7 . A structural abnormality esophagus pharynx stricture diverticulum could impede passage delivery catheter and/or endoscope . 8 . Achalasia severe esophageal motility disorder may pose safety risk removal device 9 . Severe coagulopathy 10 . Hepatic insufficiency cirrhosis 11 . Serious uncontrolled psychiatric illness disorder could compromise patient understand compliance follow visit removal device 6 month . 12 . Alcoholism drug addiction . 13 . Patients unwilling participate establish medicallysupervised diet behavior modification program , routine medical followup . 14 . Patients receive daily prescribe treatment aspirin , antiinflammatory agent , anticoagulant gastric irritant . 15 . Patients unable unwilling take prescribed proton pump inhibitor medication duration device implant . 16 . Patients know , suspect , allergic reaction material contain system . 17 . Patients ever develop serotonin syndrome currently take drug know affect level serotonin body [ e.g. , selective serotonin reuptake inhibitor ( SSRIs ) , serotoninnorepinephrine reuptake inhibitor ( SNRIs ) , monoamine oxidase inhibitor ( MAOIs ) ] undergo placement device . 18 . Patients pregnant breastfeeding . 19 . Significant endoscopic abnormality immediately prior device insertion .</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Weight Loss</keyword>
</DOC>